| 1 |
33666764 | Drug Interactions with Antihypertensives. | 2021 Mar 5 |
1 |
| 2 |
34495458 | Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making. | 2021 Nov |
1 |
| 3 |
32080863 | Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. | 2020 Jul |
2 |
| 4 |
32329770 | Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. | 2020 Apr 1 |
1 |
| 5 |
32560124 | A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug-Drug Interaction Studies. | 2020 Jun 16 |
2 |
| 6 |
29523051 | Verapamil as a culprit of palbociclib toxicity. | 2019 Apr |
1 |
| 7 |
31089348 | An Investigation into the Role of P-Glycoprotein in the Intestinal Absorption of Repaglinide: Assessed by Everted Gut Sac and Caco-2 Cell Line. | 2019 Winter |
1 |
| 8 |
31506301 | Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban. | 2019 Nov |
1 |
| 9 |
29785610 | Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes. | 2018 Dec |
1 |
| 10 |
27402157 | Physiologically Based Pharmacokinetic Modeling of Palbociclib. | 2017 Feb |
1 |
| 11 |
27939799 | The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo. | 2017 Apr |
1 |
| 12 |
26813987 | Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report. | 2016 Feb |
2 |
| 13 |
27538919 | The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model. | 2016 Nov |
3 |
| 14 |
27627192 | In Silico Predictions and In Vivo Results of Drug-Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate. | 2016 Sep |
1 |
| 15 |
26301745 | Transport and uptake of clausenamide enantiomers in CYP3A4-transfected Caco-2 cells: An insight into the efflux-metabolism alliance. | 2015 Nov 1 |
3 |
| 16 |
25571292 | A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans. | 2014 |
2 |
| 17 |
23188647 | Flavonoids and polymer derivatives as CYP3A4 inhibitors for improved oral drug bioavailability. | 2013 Feb |
1 |
| 18 |
23751364 | In-line capillary electrophoretic evaluation of the enantioselective metabolism of verapamil by cytochrome P3A4. | 2013 Jul 12 |
1 |
| 19 |
23916407 | A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. | 2013 Nov 20 |
3 |
| 20 |
21447389 | Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. | 2011 Jun 14 |
1 |
| 21 |
21716273 | Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. | 2011 Aug |
1 |
| 22 |
21832258 | Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction. | 2011 Sep |
1 |
| 23 |
20012601 | Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. | 2010 Mar |
2 |
| 24 |
20214408 | Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. | 2010 Apr |
1 |
| 25 |
19255936 | Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. | 2009 Feb |
1 |
| 26 |
19280517 | Drug-drug interaction studies in preclinical species: should metabolite(s) kinetics be studied? | 2009 Mar |
1 |
| 27 |
19307295 | Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. | 2009 Jun |
2 |
| 28 |
19444798 | A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study. | 2009 Nov |
1 |
| 29 |
18193210 | Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. | 2008 May |
4 |
| 30 |
18559486 | Blood monocyte-derived neohepatocytes as in vitro test system for drug metabolism. | 2008 Sep |
1 |
| 31 |
18661126 | Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil. | 2008 Nov |
1 |
| 32 |
17392390 | Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. | 2007 Jul |
1 |
| 33 |
16376901 | Chiral capillary electrophoretic analysis of verapamil metabolism by cytochrome P450 3A4. | 2006 Jul 7 |
2 |
| 34 |
16513446 | The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. | 2006 Mar |
3 |
| 35 |
16892180 | The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. | 2006 Oct |
1 |
| 36 |
17178259 | Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. | 2006 Dec |
2 |
| 37 |
15676042 | Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. | 2005 Feb |
1 |
| 38 |
15689501 | Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. | 2005 May |
7 |
| 39 |
15692829 | Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). | 2005 Mar |
1 |
| 40 |
15858399 | Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. | 2005 Apr |
1 |
| 41 |
15905061 | Kinetic study of CYP3A4 activity on verapamil by capillary electrophoresis. | 2005 Sep 15 |
2 |
| 42 |
16187976 | Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. | 2005 Oct |
1 |
| 43 |
16238231 | [Antihypertensive therapy and drug-drug interactions]. | 2005 Sep 14 |
1 |
| 44 |
14744940 | Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. | 2004 Feb |
1 |
| 45 |
14744949 | Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. | 2004 Feb |
8 |
| 46 |
15001968 | Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. | 2004 Mar |
1 |
| 47 |
15277015 | Homology modelling of CYP3A4 from the CYP2C5 crystallographic template: analysis of typical CYP3A4 substrate interactions. | 2004 Jun |
1 |
| 48 |
15371984 | Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. | 2004 Sep |
2 |
| 49 |
12729862 | Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers. | 2003 May |
2 |
| 50 |
12781333 | An amperometric biosensor with human CYP3A4 as a novel drug screening tool. | 2003 Jun 1 |
1 |